Developing novel antibacterials for Gram negative infections
Achaogen (NASDAQ: AKAO) is a clinical stage company focused on the discovery and development of novel antibiotics for multi-drug resistant (MDR) Gram negative bacteria. The company's lead asset, plazomicin, is in late-stage development to treat MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae that have been classified as an "urgent threat" by the CDC. Achaogen completed its IPO in 2014.
